RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Dew, Recently in one of your posts you alluded to the fact that the ability of bio financiers to do naked shorting had been severely curtailed during the current economic crisis. Since this has long been part of their MO, any thoughts on how severely this impacts raising money?

The inability to use naked shorting would presumably be less of a factor when using the registered direct approach, as opposed to an unregistered PIPE route. With the registered approach, at least the financiers don't have to sit illiquid through the post-PIPE registration period, which can last several weeks to several months. Even considering that though, wouldn't the inability to naked short still be a major disincentive for the bio financiers - a major disruption to bio finance's 'business as usual'?

Thanks for any insights.